Non-Small Cell Lung Cancer Clinical Trial
— DUBLIN-3Official title:
Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion
Verified date | September 2022 |
Source | BeyondSpring Pharmaceuticals Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. Secondary purposes of the study are: - To compare overall response rate (ORR) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. - To compare progression free survival (PFS) of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. - To compare incidence of Grade 4 neutropenia (absolute neutrophil count [ANC] < 0.5 × 109/L) on Day 8 (+/- 1 day) of Cycle 1 of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease. - To compare 24-month and 36-month OS rate of NSCLC patients receiving 2nd- or 3rd-line systemic therapy with docetaxel + plinabulin (DP Arm) to patients treated with docetaxel + placebo (D5W) (D Arm) for advanced or metastatic disease.
Status | Completed |
Enrollment | 559 |
Est. completion date | May 23, 2021 |
Est. primary completion date | March 23, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | INCLUSION CRITERIA: 1. Males and females = 18 years of age 2. ECOG performance status = 2. 3. Histopathologically or cytologically confirmed non-squamous or squamous NSCLC. 4. Disease progression during or after treatment with one or two treatment regimen(s) Treatment regimens can be chemotherapy, targeted therapy, biological therapy, or immunotherapy for advanced (Stage IIIB) or metastatic disease (Stage IV). Modification of a regimen to manage toxicity with a different drug does not constitute a new regimen. Maintenance therapy following platinum-based chemotherapy is not considered as a separate regimen. Adjuvant or neoadjuvant chemotherapy and/or chemo-radiation for early stage disease do not count as prior systemic therapy. Prior radiation therapy is not exclusionary. Prior immunotherapy with a PD-1/PD-L1 inhibitor is not exclusionary. Prior treatment for advanced or metastatic disease must have included a platinum-based regimen. (Treatment of early stage disease [Stage IIIA or earlier] with a platinum-containing therapy does not count). 5. Patients with active brain metastasis or leptomeningeal involvement with brain metastases who are asymptomatic, and whose lesions by imaging are at least stable and without interim development of new lesions for at least 4 weeks may be enrolled. Patients who require continued therapy with steroid medication for management for their brain metastases are eligible; dosing must be stable for at least 4 weeks prior to randomization; 6. Patients must have at least one measurable lung lesion of =10 mm by CT or MRI per RECIST 1.1 criteria. Radiographic tumor assessment is to be performed within 28 days prior to randomization; 7. All patients with non-squamous NSCLC must have been tested for 19 deletion and exon 21 L858R substitution mutation. Only patients without EGFR sensitizing mutations are eligible, and they must have progressed on platinum-based chemotherapy. Patients with known ALK-rearrangements should be treated with an appropriate tyrosine kinase inhibitor (TKI) before entering the study. The TKI regimen would count as a line of treatment. 8. All adverse events of any prior systemic therapy, surgery, or radiotherapy, must have resolved to CTCAE (v4.03) Grade =2, except for neurological adverse events that must have resolved to Grade =1; 9. The following laboratory results from the central laboratory within 14 days prior to Cycle 1 Day 1 study drug administration. - Hemoglobin =9 g/dL independent of transfusion or growth factor support; - Absolute neutrophil count =1.5 x 109/L independent of growth factor support; - Platelet count =100 x 109/L independent of transfusion or growth factor support; - Serum total bilirubin = ULN, unless the patient has a diagnosis of Gilbert's disease in which case serum bilirubin =3.0 times ULN; - AST and ALT =2.5 x ULN (=1.5 x ULN if alkaline phosphatase is >2.5 x ULN); - Serum creatinine =1.5 x ULN; 10. Life expectancy more than 12 weeks; 11. Female patients of childbearing potential have a negative pregnancy test at baseline. Females of childbearing potential are defined as sexually mature women without prior hysterectomy or who have had any evidence of menses in the past 12 months. However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, anti-estrogens, or ovarian suppression. 1. Women of childbearing potential (i.e., menstruating women) must have a negative urine pregnancy test (positive urine tests are to be confirmed by serum test) documented within the 24-hour period prior to the first dose of study drug. 2. Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes (a) intrauterine device (IUD) plus one barrier method; (b) on stable doses of hormonal contraception for at least 3 months (e.g., oral, injectable, implant, transdermal) plus one barrier method; (c) 2 barrier methods. Effective barrier methods are male or female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm); or (d) a vasectomized partner. 3. For male patients who are sexually active and who are partners of premenopausal women: agreement to use two forms of contraception as in criterion 11b above during the treatment period and for at least 3 months after the last dose of study drug. 12. Signed informed consent. EXCLUSION CRITERIA: Patients with any of the following: 1. Administration of chemotherapy, immunotherapy, biological, targeted, or radiation therapy or investigational agent (therapeutic or diagnostic) within 3 weeks prior to receipt of study medication. Major surgery, other than diagnostic surgery, within 4 weeks before first study drug administration. 2. Significant cardiac history: - History of myocardial infarction or ischemic heart disease within 1 year (within a window of 18 days) before first study drug administration; - Uncontrolled arrhythmia; - History of congenital QT prolongation; - ECG findings consistent with active ischemic heart disease; - New York Heart Association Class III or IV cardiac disease; - Uncontrolled hypertension: blood pressure consistently greater than 150 mm Hg systolic and 100 mm Hg diastolic in spite of antihypertensive medication. 3. Patients who have received prior treatment with docetaxel. 4. Prior transient ischemic attack or cerebrovascular accident within the past year (within an 18-day window). Any neurologic toxicities = Grade 2 within 3 weeks of randomization. 5. History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease. (Concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable). History of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility. 6. Active uncontrolled bacterial, viral, or fungal infection requiring systemic therapy. 7. Known infection with human immunodeficiency virus (HIV) or active hepatitis A, B, or C. 8. Known prior hypersensitivity reaction to any product containing polysorbate 80, polyoxyethylene 15 hydroxystearate/Macrogol 15 hydroxystearate (Solutol HS 15/ Kolliphor HS 15). 9. Female subject who is pregnant or lactating. 10. Second malignancy unless in remission for >5 years. (Non-melanoma skin cancer or carcinoma in situ of the cervix treated with curative intent is not exclusionary). 11. Any medical conditions that, in the Investigator's opinion, would impose excessive risk to the patient. Examples of such conditions include uncontrolled diabetes, infection requiring parenteral anti-infective treatment, liver failure, any altered mental status or any psychiatric condition that would interfere with the understanding of the informed consent form. 12. Unwilling or unable to comply with procedures required in this protocol. |
Country | Name | City | State |
---|---|---|---|
Australia | Blacktown Cancer Centre | Blacktown | New South Wales |
Australia | Border Medical Oncology Research Unit | East Albury | New South Wales |
Australia | Gosford Hospital | Gosford | New South Wales |
Australia | Peninsula and South East Oncology | Melbourne | Victoria |
Australia | Fiona Stanley Hospital | Murdoch | Western Australia |
Australia | Perth Oncology/Mount Hospital | Perth | Western Australia |
Australia | Epworth Hospital | Richmond | Victoria |
Australia | Adult Mater Hospital | South Brisbane | Queensland |
Australia | St John of God Hospital, Subiaco | Subiaco | Western Australia |
China | Beijing Cancer Hospital | Beijing | Beijing |
China | Cancer Hospital Chinese Academy of Medical Science | Beijing | Beijing |
China | The PLA General Hospital | Beijing | Beijing |
China | Jilin Province Cancer Hospital | Changchun | Jilin |
China | The Second Xiangya Hospital of Central South Unive | Changsha | Hunan |
China | West China Hospital of Sichuan University | Chendu | Sichuan |
China | Guizhou Provincial Hospital | Guiyang | Guizhou |
China | Affiliated Cancer Hospital of Harbin Medical Unive | Ha'erbin | Heilongjiang |
China | Sir Run Run Shaw Hospital, Zhejiang University | Hangzhou | Zhejiang |
China | Zhejiang Cancer Hospital | Hangzhou | Zhejiang |
China | The First Affiliated Hospital, Zhejiang University | Hanzhou | Zhejiang |
China | Anhui Provincial Hospital | Hefei | Anhui |
China | Jiangyin People's Hospital | Jiangyin | Jiangsu |
China | Shandong Cancer Hospital | Jinan | Shangdong |
China | 527-Linyi Cancer Hospital | Linyi | Shangdong |
China | Jiangxi Provincial Tumor Hospital | Nanchang | Jiangxi |
China | Jiangsu Cancer Hospital | Nanjing | Jiangsu |
China | Nantong Tumor Hospital | Nantong | Jiangsu |
China | Shanghai Chest Hospital, Shanghai Jiaotong Univers | Shanghai | Shanghai |
China | The Fifth People's Hospital of Shanghai | Shanghai | Shanghai |
China | Liaoning Cancer Hospital & Institute | Shenyang | Liaoning |
China | The Fourth Hospital of Hebei Medical University | Shijiazhuang | Hebei |
China | Tianjin People's Hospital | Tianjin | Tianjin |
China | Affiliated Tumor Hospital of Xinjiang Medical Univ | Ürümqi | Xinjiang |
China | The First Affiliated Hospital of Xi'an Jiaotong U | Xi'an | Shaanxi |
China | The First Affiliated Hospital of Xiamen University | Xiamen | Fujian |
China | Zhongshan Hospital Xiamen University | Xiamen | Fujian |
China | Yantai Yuhuangding Hospital | Yantai | Shangdong |
China | Henan Cancer Hospital | Zhengzhou | Henan |
United States | Pacific Cancer Medical Center, Inc. | Anaheim | California |
United States | Peachtree Hematoloy-Oncology Consultants, PC | Atlanta | Georgia |
United States | Central Care Cancer Center | Bolivar | Missouri |
United States | Ironwood Cancer & Research Centers | Chandler | Arizona |
United States | University of Cincinnati | Cincinnati | Ohio |
United States | Memorial Health Care System | Colorado Springs | Colorado |
United States | Cookeville Regional Medical Center Cancer Center | Cookeville | Tennessee |
United States | Henry Ford Hospital | Detroit | Michigan |
United States | Michigan Center of Medical Research | Farmington Hills | Michigan |
United States | Hattiesburg Clinic Hematology/Oncology | Hattiesburg | Mississippi |
United States | University of Louisville-Brown Cancer Center | Louisville | Kentucky |
United States | Allegheny Health Network | Pittsburgh | Pennsylvania |
United States | Cancer Center of Central Connecticut | Plainville | Connecticut |
United States | Orchard Healthcare Research Inc. | Skokie | Illinois |
United States | Toledo Cancer Center | Toledo | Ohio |
United States | Carle Cancer Center | Urbana | Illinois |
United States | Kansas University Medical Center | Westwood | Kansas |
United States | Innovative Clinical Research Institute | Whittier | California |
United States | Wake Forest Baptist Health | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
BeyondSpring Pharmaceuticals Inc. |
United States, Australia, China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Survival | Overall survival of NSCLC patients receiving 2nd- or 3rd-line systemic therapy | Mid-February 2021 (Approximately 2 years after study initiation) | |
Secondary | ORR | Overall response rate | Approximately 2 years after study initiation. | |
Secondary | PFS | Progress-free survival | Approximately 2 years after study initiation. | |
Secondary | Severe Neutropenia | Percent of patients without severe neutropenia on Day 8 of Cycle 1 | Day 8 of Cycle 1 | |
Secondary | Month 24 OS Rate | To compare 24-month overall survival rate | 24-month after study initiation | |
Secondary | Month 36 OS Rate | To compare 36-month overall survival rate | 36 month after study initiation | |
Secondary | DoR | Duration of response | Approximately 2 years after study initiation. | |
Secondary | Quality of Life (EORTC QLQ-C30) | Average Quality of Life score over all observed weeks (scale 0 - 30, higher value represents better outcome) | Approximately 2 years after study initiation. | |
Secondary | Q-TWiST | To compare the mean difference in quality-adjusted time without symptoms of disease and toxicity | Approximately 2 years after study initiation. | |
Secondary | QoL (QLQ-LC13) | To compare the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 global health status/QoL and the combined symptom scales/items (excluding financial difficulties) | Approximately 2 years after study initiation. | |
Secondary | Proportion of patients who received docetaxel | To compare proportion of patients who received docetaxel >8 cycles, >10 cycles, and >12 cycles | During 1st 21-day cycle | |
Secondary | Month 18 OS Rate | To compare 18-month overall survival rate | 18 month after study initiation | |
Secondary | RDI | To compare relative dose intensity [where dose intensity is defined as dose in mg/m2/week] of docetaxel | First 4, 6, 8, 10, and 12 cycles | |
Secondary | Month 12 OS Rate | To compare 12-month overall survival rate | 12 month after study initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |